title: Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.
abstract: This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide (CTX) and mitoxantrone (MXT), with dose escalation of paclitaxel. Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time.
authors: Tom Baker Cancer Centre, Calgary, Alberta, Canada.
authors: L E
authors: LE
authors: Carlson
authors: T
authors: T
authors: Koski
authors: S
authors: S
authors: Glück
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000592:standards; D001007:Anxiety / Q000209:etiology; D018771:Arthralgia / Q000209:etiology; D001859:Bone Neoplasms / Q000523:psychology / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology* / Q000523:psychology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003863:Depression / Q000209:etiology; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000523:psychology*; D006801:Humans; D008113:Liver Neoplasms / Q000523:psychology / Q000556:secondary; D008137:Longitudinal Studies; D008175:Lung Neoplasms / Q000523:psychology / Q000556:secondary; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D011788:Quality of Life; D011795:Surveys and Questionnaires; D013997:Time Factors; D014182:Transplantation, Autologous / Q000523:psychology
chemical_list: D003520:Cyclophosphamide; D008942:Mitoxantrone; D017239:Paclitaxel